Neuralink Halts Follow-Up Implant Procedure Over Health Concerns
Staff Editor
3 min read
Neuralink, the ambitious brain-chip company owned by Elon Musk, has recently hit another bump in the road. The company canceled its second human implantation surgery after identifying additional medical issues in the would-be recipient. The patient, who remains unnamed due to confidentiality laws, suffers from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. This neurodegenerative condition affects nerve cells in the brain and spinal cord, leading to a loss of muscle control.
The cancellation was confirmed by Michael Lawton, the CEO of Barrow Neurological Institute in Phoenix, which collaborated with Neuralink on both the first and the attempted second implantation. Lawton pointed out the critical nature of selecting the right patient for such pioneering trials. While he did not disclose the specific medical issues that led to the cancellation, it’s clear that the candidate was deemed unsuitable for this highly experimental procedure.
Elon Musk has been vocal about his vision of getting his own Neuralink chip implanted, but for now, the focus remains on helping people with debilitating conditions that can lead to loss of motor skills and paralysis. The company’s first patient, Noland Arbaugh, became paralyzed in all four of his limbs following a diving accident in 2016. Arbaugh’s case was groundbreaking, but it also highlighted the challenges inherent in such an ambitious endeavor. His implant began to show signs of malfunction just a few months after it was placed at the beginning of 2024.
The malfunction in Arbaugh’s implant was due to the depth of the threads embedded within his brain. Despite knowing the risk of potential failure, the company proceeded with the surgery. This decision has triggered some skepticism about the company’s readiness for broader human trials. Lawton has mentioned that a new candidate is likely to undergo the surgery next month, but details about who this individual is or what condition they suffer from remain undisclosed.
Interestingly, Neuralink has been tight-lipped about the cancellation. The company has not issued any statements nor responded to press inquiries from Bloomberg or Futurism. Musk, known for his active social media presence, has also remained silent on the matter. However, he did retweet an interview with Arbaugh, perhaps as a way to shift the focus back to the initial success of the first implantation.
Neuralink’s journey has been a rollercoaster of highs and lows. Reports have surfaced that Arbaugh’s implant started losing functionality, which underscores the complexity and risks associated with these brain-interface technologies. The company plans to embed the wires even deeper into the brain for the next patient, a daunting prospect given the complications experienced so far. The memory of ethical concerns raised during their earlier lab experiments with monkeys looms large over these human trials.
As Neuralink continues its quest to bridge the gap between human cognition and artificial intelligence, the journey will undoubtedly be fraught with both scientific and ethical challenges. The potential benefits are enormous, but the path is anything but straightforward. For now, all eyes are on the company’s next move, waiting to see if they can overcome these hurdles and make a meaningful impact in the realm of neurotechnology.
